header-logo
headshot

Anita D'Souza, MD

Professor of Medicine

Locations

  • Clinical Cancer Center - Froedtert Hospital

Specialties

  • Hematology
  • Medical Oncology

Languages

  • English, Hindi

Clinical Cancer Center - Froedtert Hospital

Education

  • MD - Doctor of Medicine

Biography

Dr Anita D’Souza is a professor of medicine (hematology and oncology). She completed her medical school from Goa Medical College, India where she graduated at the top of her class and was awarded Best Medical Graduate. She completed her internal medicine residency from William Beaumont Hospital in Michigan where she received the Zimmerman Award for Outstanding Clinical Judgment, Leadership, and Integrity. She completed her hematology/oncology fellowship from the Mayo Clinic in Rochester, MN. She is a past recipient of the Daniel McCarty Award for Research Excellent and Women in Science Rising Pioneer Award at MCW.

Research Interests

Dr. D’Souza’s clinical and research work is focused on improving outcomes of individuals living with plasma cell disorders. She is actively involved in clinical trials focused on novel immunotherapies to treat these conditions. She has an NIH-funded independent research program focused on outcome research and survivorship. Current areas of research include:

I. Development of the AL-PROfile
Funding: CTSI/AHW Mentored Career Development Award (2016-2019), K23HL1414405 (2019-2023), PD/PI: D’Souza

Publications:

  1. Development and initial validation of the AL-PROfile patient-reported outcome measure in light chain (AL) amyloidosis
  2. Differences in patient-reported outcomes (PROs) by disease severity in light chain (AL) amyloidosis
  3. A cross-sectional study of patient-reported outcomes and symptom burden using PROMIS and PRO-CTCAE measures in light chain amyloidosis
  4. Development of a conceptual model of patient-reported outcomes in light chain amyloidosis: a qualitative study
  5. The use of PROMIS patient-reported outcomes (PROs) to inform light chain (AL) amyloid disease severity at diagnosis
  6. Patient-reported outcomes - the missing link to advancing light chain (AL) amyloidosis clinical research
  7. Patient-reported satisfaction with telemedicine in light chain (AL) amyloidosis care

II. Early diagnosis of AL amyloidosis
Funding: R01HL16639 (2023-current), PD/PI: D’Souza

Publications:

  1. Timing and co-occurrence of symptoms prior to a diagnosis of light chain (AL) amyloidosis
  2. Glaucoma is not seen at a higher prevalence in age-related transthyretin amyloidosis after race stratification
  3. Racial disparities in patients diagnosed with light chain (AL) amyloidosis
  4. Prevalence of Race/Ethnicity Reporting in Light Chain (AL) Amyloidosis Clinical Research in the USA

III. Moving Forward with Multiple Myeloma
Funding: R01CA300310 (2025- current), MPI: Stolley/D’Souza/Sheehan

Publications:

  1. Exploring health behaviors and the feasibility of a lifestyle intervention for patients with multiple myeloma
  2. Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation

Publications